付款人对肿瘤治疗定价和偿付的看法

本报告对不断发展的肿瘤药物覆盖范围和定价格局进行调查分析，重点关注美国和欧洲的付款人观点。它探讨了影响付款人决策的关键考虑因素、付款人组织近期变化的影响以及与生物製药行业的关係动态。它还研究了生物相似药的作用、临床指南的影响以及行业整合和政策变化对付款人决策的潜在影响。此综合分析是基于对肿瘤学定价和偿付领域拥有丰富经验的专家的访谈。

报告内容

• 付款人在製定抗癌药物承保和定价决策时要考虑的因素
• 最近的变化如何影响付款人对肿瘤药物承保范围和定价的看法？
• 对支付者关于抗癌药物的决策影响最大的因素
• 付款人和生物製药产业如何合作改善决策过程？
• 未来可能影响肿瘤学付款人决策的问题和趋势
• 美国和欧盟支付者对肿瘤药物承保方式有何不同

主要公司

This report provides an in-depth analysis of the evolving landscape of oncology drug coverage and pricing, focusing on the perspectives of payers in the US and EU. It explores the key considerations influencing payer decisions, the impact of recent changes within payer organisations and the dynamics of their relationships with the biopharmaceutical industry. Readers will gain insights into the strategies payers employ to manage costs, including the use of innovative payment methods and the challenges posed by rising drug prices. The report also examines the role of biosimilars, the influence of clinical guidelines and the potential effects of industry consolidation and policy changes on payer decision making. This comprehensive analysis is informed by interviews with experts who have extensive experience in oncology pricing and reimbursement.

Key Questions Answered:

• 1. What are the key considerations for payers when making coverage and pricing decisions for oncology drugs?
• 2. How have recent changes influenced payer thinking about oncology drug coverage and pricing?
• 3. What factors most heavily impact changes in payer decision making for oncology drugs?
• 4. How can payers and the biopharmaceutical industry collaborate to improve decision-making processes?
• 5. What issues and trends could influence future payer decision making in oncology?
• 6. How do payers' approaches to oncology drug coverage differ between the US and EU?

Key Companies:

Partial List of Participating Experts:

• Associate Director, Office of Health Economics, UK
• Senior clinical account executive at a leading pharmacy benefit manager, US
• President and CEO, Cooperative Benefits Group
• Specialty pharmacy co-founder and oncology leader at payers in the US
• Senior Healthcare Consultant at ADVI Health and former National Medical Director, Aetna, US
• Independent consultant and experienced managed care executive, based in the US
• Senior Vice President, Specialty, Real Endpoints, US
• Venture Partner at RA Capital Management and former EVP and CMO for Harvard Pilgrim Health Care and Point32Health, a regional not-for-profit health plan in the US

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.